HUDDINGE, Sweden, Aug. 10, 2023 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that the company has entered into an agreement with a US biotechnology company. Under the agreement the parties will perform preclinical evaluation of XNK’s autologous NK cell therapy candidate…